Intimal sarcoma is a rare disease with a poor prognosis. We herein report the case of a 71-year-old man with intimal sarcoma of the pulmonary artery treated with pazopanib. The tumor showed regression after 1 month of treatment. Hand-foot syndrome led to cessation of pazopanib, which triggered a disease flare. Pazopanib should be considered in patients with intimal sarcoma of the pulmonary artery that is unresectable or recurrent after surgery or cytotoxic chemotherapy. We must be careful about drug cessation, as it can lead to a disease flare.
Introduction
Intimal sarcoma is a rare disease with a poor prognosis. The median survival has been reported to be 36.5±20.2 months for patients who underwent curative resection, compared with 11±3 months for those who underwent incomplete resection (1) . Due to its clinical manifestation, which resembles pulmonary embolism, intimal sarcoma is often misdiagnosed. We herein report the case of a 71-year-old man with intimal sarcoma of the pulmonary artery treated with pazopanib, a multitargeted tyrosine kinase inhibitor (TKI), showing a partial response to treatment. Hand-foot syndrome led to cessation of pazopanib, however. After cessation of pazopanib, the patient demonstrated a rebound effect, or a disease flare, similar to that observed in a lung cancer patient who was treated with an epidermal growth factor receptor TKI (2) (3) (4) .
Case Report
A 71-year-old man was referred to our hospital presenting with dyspnea on exertion. His medical history included hypertension, lower extremity varix, appendicitis, tuberculous lymphadenitis, and a 30 pack-year history of smoking. Plain chest computed tomography (CT) showed old inflammatory scarring of the lung, while contrast-enhanced CT revealed saddle embolism and thrombus in both the left and right main pulmonary arteries (Fig. 1) . The patient's body temperature, heart rate, and blood pressure on admission were 36.8 , 78 beats/minute, and 129/60 mmHg, respectively. Echocardiography showed a normal right ventricle chamber size, right atrial systolic pressure of 10 mmHg, tricuspid regurgitation pressure gradient of 46.1 mmHg, right ventricular systolic pressure of 46.1 mmHg, and inferior vena cava diameter of 19 mm, with respiratory variation.
These findings suggested pulmonary embolism, and anticoagulation therapy was initiated. The defect remained despite treatment, however, and his dyspnea persisted. Therefore, surgical resection of the intraluminal lesion was performed. The resected tissue was an intravascular polypoid mass extending distally along the branches of the vessels and appeared to be a soft tumor-like mass rather than a thrombus. Histologic findings revealed spindle cell sarcoma 
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with necrosis, mitotic activity, and nuclear pleomorphism. Immunohistochemical staining was focally positive for smooth muscle actin and desmin, but negative for CD31, CD34, S-100, and cytokeratin (CK) AE1/AE3. According to these findings, the tumor was diagnosed as intimal sarcoma (Fig. 2) . The tumor was completely resected. Positron emission tomography-CT performed 1 month later showed no aggregation of fluorodeoxyglucose in the pulmonary artery. Follow-up CT performed 3 months after resection revealed an intraluminal main pulmonary arterial mass invading the left pulmonary artery trunk, as well as a mass in the left lung. According to these findings, local recurrence of intimal sarcoma of the pulmonary artery was diagnosed, with suspected metastasis to the left lung.
The patient was admitted to our hospital to receive chemotherapy. On the first day of admission, he complained of acute chest pain. Contrast-enhanced CT showed left pleural effusion and rapid enlargement of the tumor in the left pulmonary artery trunk, indicating bleeding into the tumor and the left pleural space. An analgesic was administered as palliative therapy and the symptom gradually subsided.
Combination chemotherapy consisting of ifosfamide (2.5 g/m 2 on days 1-4) and doxorubicin (25 mg/m 2 on days 1-3) every 3 weeks was initiated. However, the patient suffered serious hematologic (grade 3 neutropenia) and nonhematologic (grade 3 fatigue) toxicity, and he refused to continue treatment. One month after starting first-line chemotherapy, CT revealed enlargement of the tumor, indicating progressive disease. Therefore, pazopanib 800 mg/day was started as second-line chemotherapy. One month later, shrinkage of the tumor (Fig. 3) , which met the criteria of a partial response, was demonstrated on CT. The following month, progressively worsening blisters appeared on both palms, and he was diagnosed as having hand-foot syndrome caused by pazopanib. Two months after starting pazopanib, the tumor again showed enlargement. However, we continued pazopanib therapy due to the lack of alternatives and because tumor growth suppression was still anticipated (Fig. 4) .
Four months after starting pazopanib, the patient required cessation of pazopanib because aggravation of his hand-foot syndrome made it impossible to walk (Fig. 5) . One week after cessation, the patient was admitted to the hospital for an emergency due to hemothorax (Fig. 6) and increasing pain; a disease flare was subsequently suspected. Meanwhile, discontinuation of the drug for 1 week improved his hand-foot syndrome, so pazopanib was started again. Three days after readministration of the agent, no further increase in pleural effusion or tumor size was recognized. Twelve months after the diagnosis, the patient died of intimal sarcoma.
Autopsy findings
The tumor relapsed at the site of resection, invaded into 
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the left upper lobe of the lung, and extended to the mediastinum and left thoracic cavity. In the left upper lobe of the lung, the tumor progressed along the pulmonary artery and extended to the lung parenchyma with a large cavity. Tumor cells and lung tissue with degeneration and necrosis in the cavity were observed, which were induced not only by ischemic change with tumor enlargement, but also by the effect of chemotherapy (Fig. 7) . Histologically, the tumor consisted of diffuse proliferation of spindle and pleomorphic cells with a vague fascicular storiform pattern and nuclear atypia. Immunohistochemically, the tumor cells were focally positive for smooth muscle actin, vimentin, and Ki-67 but negative for CK (AE1/AE3), CD31, CD34, desmin, myoglobin, S-100, and c-KitR.
Discussion
Sarcoma of the pulmonary artery is rare and has a poor prognosis, with a median survival of 1.5 months without surgical resection and 10 months with resection (5). Pulmonary artery sarcomas are derived from the intima. The World Health Organization has classified intimal sarcoma as myofibroblastic sarcoma without angiosarcoma.
Although some reports have shown that chemotherapy or radiotherapy is effective against pulmonary artery sarcoma, its role in the treatment of unresectable intimal sarcoma or relapsed sarcoma remains uncertain (6) (7) (8) . In this case, we used combination doxorubicin and ifosfamide as first-line chemotherapy and pazopanib as second-line chemotherapy. Pazopanib is a multitargeted TKI with a high affinity against vascular endothelial growth factor receptor-1/2/3 and a lower affinity against platelet-derived growth factor receptor-α/β, fibroblast growth factor receptor-1/2, and stem cell factor receptor c-KitR (9-11). A phase III trial of pazopanib against soft tissue sarcoma was performed in 2012. The effect of pazopanib on patients with metastatic nonadipocytic soft tissue sarcoma was assessed. The median progression-free survival was 4.6 months (range, 3.7-4.8) with pazopanib compared with 1.6 months (range, 0.9-1.8) with placebo [hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.24-0.40; p <0.0001]. The overall survival was 12.5 months (range, 10.6-14.8) with pazopanib versus 10.7 months (range, 8.7-12.8) with placebo (HR, 0.86; 95% CI, 0.67-1.11; p= 0.25) (12) . In 2012, pazopanib was approved by the Ministry of Health, Labour and Welfare of Japan.
In this case, initial tumor shrinkage met the criteria for a partial response. Thus, pazopanib was thought to be at least transiently effective. Rapid enlargement of the tumor was observed during the period of pazopanib cessation, indicating a rebound flare. Although a disease flare due to cessation of epithelial growth factor receptor-TKI for lung cancer has been reported, a disease flare due to cessation of TKI for intimal sarcoma has not.
The efficacy of chemotherapy for the treatment of intimal sarcoma is limited; thus, pazopanib should be considered in patients with sarcoma of the pulmonary artery that is unresectable or recurrent after surgery or cytotoxic chemotherapy. In such cases, we should be careful about drug cessation because it can lead to a disease flare. However, in cases where the interruption of therapy is unavoidable, we should The authors state that they have no Conflict of Interest (COI).
